HBOT and Menopause: What the Research Shows About Brain Health, Symptoms and Quality of Life

Menopause is a universal experience for women, yet it remains one of the most underserved transitions in medicine. The hormonal changes of perimenopause and menopause affect virtually every system in the body, and the symptoms that accompany them, cognitive changes, sleep disruption, mood instability, fatigue, vasomotor symptoms, and an increased risk of cardiovascular and neurodegenerative disease, can be significant and prolonged.

The medical response to this transition has historically focused on hormonal management, with hormone replacement therapy remaining the most evidence-based intervention for many symptoms. But a substantial proportion of women either cannot use hormonal therapy, choose not to, or find that it does not adequately address the neurological and cognitive dimensions of their experience. It is in this context that interest in hyperbaric oxygen therapy has grown, and where a small but meaningful body of research has begun to produce findings worth examining carefully.

The Neurobiology of Menopause

Understanding why HBOT might be relevant to menopause requires understanding what oestrogen actually does in the brain, because the neurological effects of oestrogen withdrawal are more extensive than is commonly appreciated.

Oestrogen is not simply a reproductive hormone. It has widespread effects on the central nervous system, including roles in cerebral blood flow regulation, neuroinflammation modulation, mitochondrial function, synaptic plasticity, and the protection of neurons against oxidative stress. Oestrogen receptors are distributed throughout the brain, with particularly high concentrations in the hippocampus, prefrontal cortex, and hypothalamus, regions involved in memory, executive function, emotional regulation, and the control of vasomotor responses.

When oestrogen levels decline during perimenopause and menopause, these neuroprotective effects are reduced. Cerebral blood flow decreases. Neuroinflammation increases. Mitochondrial efficiency in neurons falls. The brain's vulnerability to oxidative stress rises. These changes are not merely theoretical; they are visible on functional brain imaging and they correlate with the cognitive and mood symptoms that many women experience during this transition.

This is the biological context in which HBOT becomes relevant. HBOT promotes cerebral blood flow, reduces neuroinflammation, supports mitochondrial function, and activates antioxidant defence systems. These are precisely the mechanisms that oestrogen withdrawal compromises.

The Research: What Has Been Studied

The most directly relevant published work comes from the Sagol Center for Hyperbaric Medicine and Research in Israel, the same group whose research on HBOT and ageing, neurological conditions, and fibromyalgia has been discussed elsewhere on this site.

A study published in 2022 in the journal Aging examined the effects of HBOT specifically in postmenopausal women. The study enrolled 40 postmenopausal women aged 40 to 70 who were not using hormone replacement therapy. Participants received 60 sessions of HBOT at 2.0 ATA with 100% oxygen, each session lasting 90 minutes, conducted five days per week over 12 weeks.

The findings were meaningful across several domains.

Cognitive function improved significantly, with gains in attention, information processing speed, executive function, and memory. These improvements were measured using validated neuropsychological assessments and were accompanied by changes on brain imaging, including increased cerebral blood flow in regions associated with the cognitive domains that improved.

Quality of life measures showed significant improvements, including reductions in fatigue, improvements in sleep quality, and improvements in overall wellbeing scores.

Biological markers of ageing showed changes consistent with the group's earlier work in healthy older adults: telomere length increased and senescent cell burden decreased in the treated group. Given that menopause accelerates several biological ageing processes, this finding is particularly relevant.

The study also examined brain tissue volume using MRI. The HBOT group showed increases in grey matter volume in regions that typically atrophy with age and with the hormonal changes of menopause, including the hippocampus and prefrontal cortex.

Why the Cognitive Dimension Matters

The cognitive symptoms of perimenopause and menopause are among the most distressing and least discussed aspects of this transition. Many women describe a period of cognitive change during perimenopause, including difficulties with memory, word finding, concentration, and mental clarity, that can be alarming and that is often inadequately addressed in clinical consultations.

The research on oestrogen and brain function suggests that these symptoms are not imagined and not simply a consequence of poor sleep or mood changes, though those factors contribute. They reflect real neurobiological changes driven by oestrogen withdrawal, changes that are measurable on imaging and that correlate with the hormonal trajectory of the transition.

The HBOT findings are relevant here because they suggest that the neurobiological changes associated with menopause, reduced cerebral blood flow, increased neuroinflammation, mitochondrial dysfunction, are amenable to intervention through mechanisms that do not depend on hormonal replacement. This is significant for women who cannot or choose not to use hormone therapy, and it is significant for the cognitive and neurological dimensions of menopause that hormone therapy does not always fully address.

The Broader Ageing Context

Menopause does not simply produce symptoms. It also marks a transition point in the trajectory of several age-related disease risks.

The decline in oestrogen at menopause is associated with accelerated cardiovascular risk, increased risk of osteoporosis, and, importantly, an increased risk of Alzheimer's disease and other dementias. Women have a higher lifetime risk of Alzheimer's disease than men, and the hormonal changes of menopause are increasingly recognised as a contributing factor, not merely a reflection of longer average lifespan.

The neurobiological changes that HBOT appears to address, reduced cerebral blood flow, neuroinflammation, mitochondrial dysfunction, and accelerated cellular ageing, are the same mechanisms implicated in this elevated dementia risk. Whether HBOT in the menopausal transition could influence long-term neurodegenerative risk is a question that the current research does not answer, but it is a question that the mechanistic picture makes worth asking.

The telomere and senescent cell findings from the 2022 study are relevant here. Menopause accelerates biological ageing at the cellular level, and the reversal of these markers in the HBOT group is consistent with the broader longevity research discussed in the ageing article on this site.

Perimenopause: The Transition Before the Transition

It is worth addressing perimenopause specifically, because it is a distinct phase with its own clinical profile that is often inadequately recognised and managed.

Perimenopause, the years of hormonal fluctuation preceding the final menstrual period, can last anywhere from two to ten years. During this phase, oestrogen levels do not simply decline; they fluctuate erratically, producing a pattern of hormonal variability that many women find more disruptive than the more stable low-oestrogen state of established menopause.

The neurological effects of this fluctuation are significant. The brain's oestrogen receptors are sensitive to hormonal variability, and the erratic signalling of perimenopause can produce cognitive and mood symptoms that are sometimes more pronounced than those of established menopause. Sleep disruption during perimenopause, driven by vasomotor symptoms and hormonal fluctuation, compounds the neurological impact.

The HBOT research has focused primarily on postmenopausal women rather than perimenopausal women, which means the evidence is less direct for this phase of the transition. However, the mechanisms being addressed, cerebral blood flow, neuroinflammation, mitochondrial function, are relevant throughout the transition, and the rationale for HBOT in perimenopause is mechanistically coherent even where the specific evidence is less developed.

What the Evidence Does Not Show

The research on HBOT and menopause is genuinely promising, and the mechanistic rationale is coherent. It is not yet sufficient to establish HBOT as a standard treatment for menopausal symptoms or as a validated neuroprotective intervention for this population.

The 2022 study enrolled 40 women. This is a small sample, and independent replication in larger populations is needed. The study population was postmenopausal women not using hormone therapy; the findings cannot be straightforwardly extrapolated to perimenopausal women or to women using hormonal management concurrently.

The study did not directly compare HBOT to hormone replacement therapy, which remains the most evidence-based intervention for many menopausal symptoms. The relevant clinical question for many women is not whether HBOT works in isolation but how it fits within a broader management approach that may or may not include hormonal therapy.

The study measured cognitive function, quality of life, and biological markers. It did not measure long-term outcomes such as dementia incidence, cardiovascular events, or bone density. The assumption that improving these intermediate markers translates into meaningful long-term health benefits is biologically plausible but has not been directly demonstrated.

What This Means in Practice

For women considering HBOT in the context of perimenopause or menopause, several practical points are worth understanding clearly.

The evidence is most developed for postmenopausal women not using hormone therapy. This is the population studied in the published research. Women in perimenopause, or those using hormonal management, are not the population in which this evidence was generated, though the mechanistic rationale extends to them.

HBOT is not a replacement for hormonal management where that is appropriate. Hormone replacement therapy has a substantial evidence base for vasomotor symptoms, bone health, and cardiovascular risk in appropriate candidates. HBOT addresses different mechanisms and should be considered as a complement to, not a substitute for, evidence-based hormonal management where that is clinically suitable.

The protocol is demanding. The research used 60 sessions at 2.0 ATA, five days per week over 12 weeks. This is a significant commitment of time and logistics, and the clinical-grade hard-shell chamber required is not the same as a soft-shell wellness chamber. The evidence should not be assumed to apply to lower-pressure protocols.

A thorough clinical assessment should precede treatment. The menopausal transition involves a complex interplay of hormonal, metabolic, cardiovascular, and neurological changes. A proper clinical evaluation, including assessment of cardiovascular risk, hormonal status, and cognitive baseline, is appropriate before beginning a course of HBOT.

The cognitive and neurological dimensions deserve specific attention. Many women find that the cognitive symptoms of perimenopause and menopause are inadequately addressed in standard clinical care. If these are the primary concern, a neurological assessment and, where appropriate, functional brain imaging can establish a baseline and help determine whether HBOT is likely to be relevant for the specific presentation.

An Honest Assessment

The HBOT menopause research is among the more interesting recent additions to the literature on this transition. A study demonstrating improvements in cognitive function, quality of life, brain tissue volume, and biological ageing markers in postmenopausal women, using a well-characterised protocol, is a meaningful finding. It is not definitive, and larger independent trials are needed, but it is substantive enough to take seriously.

What makes the evidence particularly compelling is the mechanistic coherence. The neurobiological changes of menopause, reduced cerebral blood flow, neuroinflammation, mitochondrial dysfunction, accelerated cellular ageing, are precisely the mechanisms that HBOT is known to address in other contexts. The menopause findings are consistent with what the broader HBOT literature would predict.

For women navigating perimenopause or menopause who are looking for approaches that address the neurological and cognitive dimensions of this transition, particularly those who cannot or choose not to use hormone therapy, HBOT represents a credible option worth exploring with appropriate clinical guidance.